Table of Contents

1 Study Coverage

• 1.1 Ophthalmology Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Ophthalmology Drugs Market Size Growth Rate by Product
  • 1.4.2 Gels
  • 1.4.3 Eye Solutions
  • 1.4.4 Capsules & Tablets
  • 1.4.5 Eye Drops
  • 1.4.6 Ointments
• 1.5 Market by End User
  • 1.5.1 Global Ophthalmology Drugs Market Size Growth Rate by End User
  • 1.5.2 Hospital
  • 1.5.3 Retail Pharmacy
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Ophthalmology Drugs Market Size
  • 2.1.1 Global Ophthalmology Drugs Revenue 2014-2025
  • 2.1.2 Global Ophthalmology Drugs Sales 2014-2025
• 2.2 Ophthalmology Drugs Growth Rate by Regions
  • 2.2.1 Global Ophthalmology Drugs Sales by Regions
  • 2.2.2 Global Ophthalmology Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Ophthalmology Drugs Sales by Manufacturers
  • 3.1.1 Ophthalmology Drugs Sales by Manufacturers
  • 3.1.2 Ophthalmology Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Ophthalmology Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Ophthalmology Drugs Revenue by Manufacturers
  • 3.2.1 Ophthalmology Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Ophthalmology Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Ophthalmology Drugs Price by Manufacturers
• 3.4 Ophthalmology Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Ophthalmology Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Ophthalmology Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Ophthalmology Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Ophthalmology Drugs Sales by Product
• 4.2 Global Ophthalmology Drugs Revenue by Product
• 4.3 Ophthalmology Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Ophthalmology Drugs Breakdown Data by End User

6 North America

• 6.1 North America Ophthalmology Drugs by Countries
  • 6.1.1 North America Ophthalmology Drugs Sales by Countries
  • 6.1.2 North America Ophthalmology Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Ophthalmology Drugs by Product
• 6.3 North America Ophthalmology Drugs by End User

7 Europe

• 7.1 Europe Ophthalmology Drugs by Countries
  • 7.1.1 Europe Ophthalmology Drugs Sales by Countries
  • 7.1.2 Europe Ophthalmology Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Ophthalmology Drugs by Product
• 7.3 Europe Ophthalmology Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Ophthalmology Drugs by Countries
  • 8.1.1 Asia Pacific Ophthalmology Drugs Sales by Countries
  • 8.1.2 Asia Pacific Ophthalmology Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Ophthalmology Drugs by Product
• 8.3 Asia Pacific Ophthalmology Drugs by End User

9 Central & South America

• 9.1 Central & South America Ophthalmology Drugs by Countries
  • 9.1.1 Central & South America Ophthalmology Drugs Sales by Countries
  • 9.1.2 Central & South America Ophthalmology Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Ophthalmology Drugs by Product
• 9.3 Central & South America Ophthalmology Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Ophthalmology Drugs by Countries
  • 10.1.1 Middle East and Africa Ophthalmology Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Ophthalmology Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Ophthalmology Drugs by Product
• 10.3 Middle East and Africa Ophthalmology Drugs by End User

11 Company Profiles

• 11.1 Allergan
  • 11.1.1 Allergan Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Allergan Ophthalmology Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Allergan Ophthalmology Drugs Products Offered
  • 11.1.5 Allergan Recent Development
• 11.2 Aerie Pharmaceuticals
  • 11.2.1 Aerie Pharmaceuticals Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Aerie Pharmaceuticals Ophthalmology Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Aerie Pharmaceuticals Ophthalmology Drugs Products Offered
  • 11.2.5 Aerie Pharmaceuticals Recent Development
• 11.3 Pfizer
  • 11.3.1 Pfizer Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Pfizer Ophthalmology Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Pfizer Ophthalmology Drugs Products Offered
  • 11.3.5 Pfizer Recent Development
• 11.4 Valeant
  • 11.4.1 Valeant Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Valeant Ophthalmology Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Valeant Ophthalmology Drugs Products Offered
  • 11.4.5 Valeant Recent Development
• 11.5 Bayer
  • 11.5.1 Bayer Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Bayer Ophthalmology Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Bayer Ophthalmology Drugs Products Offered
  • 11.5.5 Bayer Recent Development
• 11.6 Genentech
  • 11.6.1 Genentech Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Genentech Ophthalmology Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Genentech Ophthalmology Drugs Products Offered
  • 11.6.5 Genentech Recent Development
• 11.7 Novartis
  • 11.7.1 Novartis Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Novartis Ophthalmology Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Novartis Ophthalmology Drugs Products Offered
  • 11.7.5 Novartis Recent Development
• 11.8 Regeneron
  • 11.8.1 Regeneron Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Regeneron Ophthalmology Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Regeneron Ophthalmology Drugs Products Offered
  • 11.8.5 Regeneron Recent Development
• 11.9 Shire
  • 11.9.1 Shire Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Shire Ophthalmology Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Shire Ophthalmology Drugs Products Offered
  • 11.9.5 Shire Recent Development
• 11.10 Santen Pharmaceutical
  • 11.10.1 Santen Pharmaceutical Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Santen Pharmaceutical Ophthalmology Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Santen Pharmaceutical Ophthalmology Drugs Products Offered
  • 11.10.5 Santen Pharmaceutical Recent Development

12 Future Forecast

• 12.1 Ophthalmology Drugs Market Forecast by Regions
  • 12.1.1 Global Ophthalmology Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Ophthalmology Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Ophthalmology Drugs Market Forecast by Product
  • 12.2.1 Global Ophthalmology Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Ophthalmology Drugs Revenue Forecast by Product 2019-2025
• 12.3 Ophthalmology Drugs Market Forecast by End User
• 12.4 North America Ophthalmology Drugs Forecast
• 12.5 Europe Ophthalmology Drugs Forecast
• 12.6 Asia Pacific Ophthalmology Drugs Forecast
• 12.7 Central & South America Ophthalmology Drugs Forecast
• 12.8 Middle East and Africa Ophthalmology Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Ophthalmology Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Drugs for ophthalmology, which are used to treat eye conditions and eye diseases such as glaucoma, conjunctivitis and others.
The global Ophthalmology Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Ophthalmology Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Ophthalmology Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Ophthalmology Drugs in these regions.
This research report categorizes the global Ophthalmology Drugs market by top players/brands, region, type and end user. This report also studies the global Ophthalmology Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Allergan
Aerie Pharmaceuticals
Pfizer
Valeant 
Bayer
Genentech
Novartis
Regeneron
Shire
Santen Pharmaceutical

Market size by Product
Gels
Eye Solutions
Capsules & Tablets
Eye Drops
Ointments
Market size by End User
Hospital
Retail Pharmacy

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Ophthalmology Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Ophthalmology Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Ophthalmology Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Ophthalmology Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Ophthalmology Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Ophthalmology Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.